Anti-SOX1 Antibody-positive Small-cell Lung Cancer That Triggered Opsoclonus.

A 72-year-old woman with opsoclonus visited our hospital and was diagnosed with small-cell lung cancer. Blood tests revealed anti-SOX1 antibodies, so the patient was diagnosed with paraneoplastic opsoclonus-myoclonus syndrome. After steroid pulse therapy was started, chemotherapy of treatment, the opsoclonus showed an improving trend. Anti-Ri and anti-Hu antibodies have been reported as autoantibodies associated with neoplastic opsoclonus-myoclonus syndrome; however, there are no such reports concerning anti-SOX1 antibody. Therefore, this is a valuable case.

Performance of stacked microbial fuel cells with barley-shochu waste.

The treatment of barley-shochu waste combined with electricity generation was examined using stacked microbial fuel cells (SMFCs). The maximum chemical oxygen demand (CODCr) removal efficiency and maximum power density were achieved at 36.7 ± 1.1% and 4.3 ± 0.2 W m⁻³ (15.7 ± 0.9 mW m-2). The acetic acid concentration in effluent increased, whereas the citric acid, ethanol and sugar concentrations decreased during the operation. Microbial community analysis of the anode cell suspension and raw barley-shochu waste revealed that Clostridiaceae, Acetobacteraceae, and Enterobacteriaceae became predominant after the operation, implying that microorganisms belonging to these families might be involved in organic waste decomposition and electricity generation in the SMFCs.

Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir.

COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.